Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026
Same author

Dual CAR-T cell therapy targeting CD19 and BCMA as a novel opportunity for immune reset in systemic lupus erythematosus.

Cellular & molecular immunology·2026
Same author

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

bioRxiv : the preprint server for biology·2026
Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026

相关实验视频

Updated: Mar 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K

治疗T细胞工程

Michel Sadelain1, Isabelle Rivière1, Stanley Riddell2

  • 1Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

Nature
|May 26, 2017
PubMed
概括
此摘要是机器生成的。

基因工程T细胞使用化学抗原受体 (CARs) 显示出治疗癌症的前景. 进一步的研究旨在通过解决抗原向和瘤微环境等挑战来扩大它们在各种疾病中的使用.

更多相关视频

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

相关实验视频

Last Updated: Mar 1, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.0K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

科学领域:

  • 免疫学
  • 癌症学
  • 生物技术

背景情况:

  • 基因工程T细胞代表了癌症治疗的重大进步.
  • 化学抗原受体 (CAR) 是重定向T细胞活动的合成受体.
  • 针对CD19的CAR在B细胞恶性瘤中具有很高的疗效.

研究的目的:

  • 审查基于T细胞的疗法的潜力和挑战.
  • 突出T细胞工程和制造方面的进步.
  • 探索癌症治疗之外的未来应用.

主要方法:

  • 对CAR T细胞治疗的当前文献的综述.
  • 对B细胞恶性瘤的成功分析.
  • 讨论固体瘤和其他疾病的挑战.

主要成果:

  • 特别是针对CD19的CAR T细胞对B细胞癌症有效.
  • 仍然存在重大障碍,包括抗原识别,瘤微环境调节,毒性和抗原逃逸.
  • 在T细胞选择,基因工程和制造方面的进步至关重要.

结论:

  • 工程T细胞疗法对各种癌症具有很大的潜力.
  • 克服目前的局限性是更广泛的临床应用的关键.
  • 未来的应用可能会扩展到传染病和自身免疫性疾病.